VRTX - Vertex Pharmaceuticals Inc
A biotechnology company that transformed cystic fibrosis treatment with its Trikafta franchise, and is now expanding into pain management and other genetic diseases.
Finlify Score
48.0 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$515.44
+0.17%
52W Range
$374.17 - $560.25
Market Cap
$121.1B
+0.2%Compared to previous day
2026 Q1 Revenue
$3.0B
-6.4%Changes from last reporting quarter
2026 Q1 EPS
$4.02
Diluted shares
Analyst Rating
36 analysts in latest ratings feed
RSI
29.1
<40 oversold
2Y Range Position
77%
-8.0% from high / +42.2% from low
Beta
0.29
Relative to market benchmark
MACD
-5.96
MACD line 5.04 / signal line 11.00
Fundamental Trend
Growth 31.2Financial Health
Quality 73.4Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD48.0 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $3.0B-6.4% | $3.2B+3.7% | $3.1B+3.8% | $3.0B+7.0% |
| Gross Profit | - | - | - | - |
| Operating Income | $1.1B-5.6% | $1.2B+1.7% | $1.2B+3.0% | $1.2B+82.7% |
| Net Income | $1.0B-13.4% | $1.2B+10.0% | $1.1B+4.8% | $1.0B+59.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
The Finlify signal for VRTX is HOLD, with an overall Finlify Score of 48.7/100, suggesting a neutral stance on the asset as of 2026-07-30.
Technical
The Relative Strength score of 28.2/100 appears relatively low, potentially indicating underperformance compared to peers. However, the Accumulation / Volume score of 85.8/100 suggests strong buying interest. The asset has seen a 20-day return of -3.3% but a 60-day return of 12.1%, with its RSI at 51.1, indicating a somewhat neutral momentum and a -9.0% distance from its 52-week high.
Fundamentals
The Fundamental Trend score of 31.2/100 appears modest, while the Financial Quality score of 73.4/100 suggests a solid financial foundation. Valuation metrics such as a P/E of 30.5x, P/B of 6.2x, and P/S of 10.0x may indicate a premium valuation. VRTX exhibits a low Beta of 0.3, suggesting lower sensitivity to broader market movements.
Macro Context
Given VRTX's low Beta of 0.3, it may exhibit some resilience to broader economic shifts. While inflation metrics like CPI YoY at 3.7% and Core PCE YoY at 3.3% remain elevated, the positive yield spread of 0.5% (10Y-2Y) could suggest a less tightening financial environment, potentially favorable for growth-oriented sectors.
Key Risks
- Upcoming earnings report on 2026-08-03 introduces potential volatility.
- The relatively low Relative Strength score of 28.2/100 may indicate recent underperformance compared to its peers.
- Valuation metrics such as P/E of 30.5x and P/S of 10.0x appear elevated, potentially limiting upside if growth expectations are not met.